PARK7

Across TCGA pan-cancer cohorts, PARK7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PARK7 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PARK7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PARK7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where PARK7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.543	0.340	.003	24	view →
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	12	view →
LUAD	DFS	Tertile	All	0.788	0.280	.002	11	view →
GBM	DFS	Tertile	All	0.225	0.473	.021	6	view →
LSCC	DFS	Tertile	II,III,IV	0.616	0.849	.032	4	view →
HNSC	DFS	Median	All	0.903	0.979	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PARK7–PDAC (DFS)

Open the PDAC breakdown →